Author

SJ Snedecor

Observed institution: Pharmerit (United States)

OpenAlex ID: A5110083280

Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy

2015 · A Aiello, F Daniel, et al. · Value in Health · 4

PDF

EE231 Calculating the Indirect Cost of Disease Recurrence and Subsequent Premature Mortality in Patients Diagnosed with Early-Stage Hepatocellular Carcinoma (HCC) in the United States (US)

2022 · V Ektare, S Hegde, et al. · Value in Health · 1

PDF

Use of the Weibull Proportional Hazards Model to Estimate OS and PFS in 9 Blood Cancer Indications: Validation and Violation

2018 · D Nicoloso, C Zhang, et al. · Value in Health · 1

Puk8 Fesoterodine Is Cost-effective for the Treatment of Overactive Bladder: Results of an Economic Model

2008 · C Kelleher, SJ Snedecor, et al. · Value in Health · 1

Ini Cost Effectiveness of Hivtreatment Innovations of Greater Efficacy Than Highly Active Antiretroviral Therapy (haart)

2005 · SJ Snedecor, A Hartzema, et al. · Value in Health · 1

PDF

EE501 Making R-Based Economic Models Even Shinier With Web-Based Interfaces

2022 · SJ Snedecor, D Kratochvil · Value in Health

MSR31 Evidence Synthesis for Decision-Making: Is Meta-Analysis Always Required?

2022 · SJ Snedecor · Value in Health

PDF

MSR47 A Stepwise Approach for Assessing the Feasibility of Population-Adjusted Indirect Treatment Comparisons

2022 · M Lambton, K Nickel, et al. · Value in Health

SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

2022 · SJ Snedecor, M Mersky, et al. · Value in Health

EE106 Evaluation of Full Factorial and Latin Hypercube Sampling As Alternatives to Traditional Random Selection for Probabilistic Uncertainty Analyses

2022 · AE Barkema, SJ Snedecor · Value in Health

EE344 Estimating the Utilization of and Expenditure on the Newly Approved Injectable Prep Required to Meet the "End the HIV Epidemic in the US” 2030 Goal of 90% Reduction in New HIV Infections

2022 · HY Yang, SJ Snedecor · Value in Health

PDF

POSC64 Healthcare Costs and Resource Utilization in 1L Maintenance (1L MT) Treatment (Tx) of Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review

2022 · D Heldt, SJ Snedecor, et al. · Value in Health

Comparative Efficacy of Time to Virologic Suppression in Treatment-Naive HIV-1 Patients: A Network Meta-Analysis of Longitudinal Data

2016 · SJ Snedecor · Value in Health

Pmc34 Serotype-specific Transmission Dynamics of Invasive Pneumococcal Disease After Vaccination With 7-valent Pneumococcal Conjugate Vaccine

2009 · SJ Snedecor, MF Botteman, et al. · Value in Health

PDF

Mo1 Impact of Including Cardiovascular and Respiratory Outcomes on Estimates of Clinical and Economic Benefits of Influenza Vaccination in the U.s. Elderly Population

2009 · X Gao, SJ Snedecor, et al. · Value in Health

PDF

Puk8 a Review: Differing Costs and Effects in Economic Evaluations of Tolterodine for the Treatment of Overactive Bladder

2008 · SJ Snedecor, MF Botteman, et al. · Value in Health

PDF

Pnd28 Comparison of Four Preference-based Sf-36/sf-i2 Algorithms to Evaluate the Cost-effectiveness of Treatment for Primary Insomnia With Eszopiclone

2007 · SJ Snedecor, MF Botteman, et al. · Value in Health

PDF

Pnd7 an Analytical Model to Predict the Cost-effectiveness of Long-term Eszopiclone for the Treatment of Primary Insomnia

2007 · SJ Snedecor, MF Botteman, et al. · Value in Health

PDF

Works count: 18

Citation count: 8

H-index: 1

I10-index: